World Diabetes Foundation (WDF) highlights phenomenal real-world clinical results delivered by EyeArt in Armenia
Aug 25, 2020: Eyenuk, Inc. is honored to be highlighted by World Diabetes Foundation for phenomenal real-world clinical results delivered with Armenia Eye Care Project (AECP). Of the 16,000 people screened by Eyenuk’s EyeArt AI…
Eyenuk is honored to be featured as the latest “Small Business Success Story” by the National Institute of Health (NIH). Eyenuk’s innovations have been supported by significant grant funding from NIH covering artificial intelligence for…
EyeArt is the First FDA Cleared AI Technology for Autonomous Detection of Both More than mild and Vision-Threatening Diabetic Retinopathy Los Angeles, CA, August 5, 2020 — Eyenuk, Inc., a global artificial intelligence (AI) medical…
Artificial intelligence could help prevent eye damage and sight loss in people with diabetes and save NHS millions of pounds annually MONDAY 6THJULY 2020 Results from the largest study of artificial intelligence use in the…
Multinational Optical Retailer Piloting AI and Telemedicine Technology to Protect Community Eye Health During the COVID-19 Pandemic
Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screening Los Angeles, CA, June 8, 2020 — Eyenuk, Inc. and Devlyn Optical, a spin-off of Grupo Devlyn, a multinational optical retailer with over one thousand…
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.